



# HLS

# PLATELET DISORDERS

---


DR.EMAN KREISHAN, M.D.

15-4-2026


# PLATELET DISORDERS

---

- The platelets arise from the fragmentation of the cytoplasm of megakaryocytes in the bone marrow and circulate in blood as disc-shaped anucleate particles for 7-10 days.
- Platelet disorders lead to defects in primary hemostasis and produce signs and symptoms different from coagulation factor deficiencies (disorders of secondary hemostasis).
- Isolated thrombocytopenia is associated with a bleeding tendency and normal coagulation tests.




# Major Components of Hemostasis



# Formation of a Hemostatic Plug

## Primary Hemostasis

## Secondary Hemostasis




# Relationship Between Platelet Count and Bleeding

---



- Normal range  $150-450 \times 10^3$  per  $\mu\text{l}$ .
- Levels above  $60 \times 10^3/\mu\text{l}$  will not cause bleeding under normal conditions.
- Levels below  $20 \times 10^3/\mu\text{l}$  will cause:
  - Petechiae, mucosal bleeding.
  - Post-operative bleeding, CNS bleeding.
- Levels around  $5 \times 10^3/\mu\text{l}$  can lead to fatal CNS or GI hemorrhage.
- Levels between  $20$  and  $60 \times 10^3/\mu\text{l}$  may cause bleeding (depending on platelets functional status).

## Common causes of acquired thrombocytopenia



**Table 12.13 Causes of Thrombocytopenia**

**Decreased Production of Platelets**

**Generalized Bone Marrow Dysfunction**

Aplastic anemia: congenital and acquired

Marrow infiltration: leukemia, disseminated cancer

**Selective Impairment of Platelet Production**

Drug-induced: alcohol, thiazides, cytotoxic drugs

Infections: measles, HIV infection

**Ineffective Megakaryopoiesis**

Megaloblastic anemia

Paroxysmal nocturnal hemoglobinuria

**Decreased Platelet Survival**

**Immunologic Destruction**

Autoimmune: ITP, systemic lupus erythematosus

Isoimmune: posttransfusion and neonatal

Drug-associated: quinidine, heparin, sulfa compounds

Infections: infectious mononucleosis, HIV infection, cytomegalovirus infection

**Nonimmunologic Destruction**

Disseminated intravascular coagulation

TTP

Giant hemangiomas

Microangiopathic hemolytic anemias

**Sequestration**

Hypersplenism

**Dilutional**

Multiple transfusions (e.g., for massive blood loss)

# 1. Immune thrombocytopenia (ITP)

---

- Immune thrombocytopenia (ITP) is one of the most common autoimmune disorders.
- ITP is caused by autoantibodies to platelets. The antigenic target is platelet GP IIb/IIIa complex.
- These antibodies may be directed toward viral antigens and then :
  - cross-react with platelet antigens then they trapped in the spleen, and efficiently removed by splenic macrophages.
- Or:
  - react with the developing megakaryocytes in the bone marrow, leading to ineffective thrombopoiesis.

# ITP

---

- ▶ Primary (idiopathic) or secondary
- ▶ Acute (self limiting) or chronic.

# Acute ITP (Idiopathic/Childhood)

---

- ❖ Usually Affects children.
- ❖ Develops acutely with 1-2 week duration.
- ❖ Presented as Bruising and petechia
- ❖ Preceded by infection or vaccination in 75% of cases.
- ❖ Initial Platelet .count <20,000.
- ❖ Self limited, Spontaneous remission in >90% of cases.
- ❖ Severe cases benefit from steroids or IV immunoglobulins.

# Chronic Immune Thrombocytopenic Purpura (ITP)

---

- ❖ High incidence in women of child bearing age (20-50).
- ❖ NO recent history of drug or recent infection.
- ❖ Mostly idiopathic, secondary causes include SLE, HIV, CLL, Hodgkin's disease, drugs (uncommon).
- ❖ Autoantibodies against GP IIb/IIIa.
- ❖ Platelets lifespan reduced to hours.
- ❖ Megakaryocytes increased.
- ❖ Petechial bleeding, easy bruising, menorrhagia.

# DIAGNOSIS

\* On CBC:



Decreased platelet count ( $10-50 \times 10^9/l$ ), normal Hb and WBCs.

\* Peripheral blood: large platelet.

\* Bone marrow: Increased Megakaryocytes numbers.

\* Bleeding time: : Mild prolongation.

\* Assay for Antiplatelet antibodies.



# Treatment


Steroids.

Splenectomy (long term Rx.).

High dose IV immunoglobulins.

Immunosuppressive therapy.

## Immune Thrombocytopenic Purpura (ITP)



### Other Symptoms May Include:

- Bleeding from the nose and gums
- Black blisters in the mouth
- Heavy menstrual periods
- Fatigue

## 2. Microangiopathic Thrombocytopenia TTP/HUS


---

The term thrombotic microangiopathies encompasses a spectrum of clinical syndromes that include :

- Thrombotic thrombocytopenic purpura (TTP) .
- Hemolytic uremic syndrome (HUS).


# Thrombotic thrombocytopenic purpura (TTP)

- Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels (thromboses), resulting in a low platelet count.
- The classic histologic lesion is one of bland thrombi in the microvasculature of affected organs. These thrombi consist predominantly of platelets, with little fibrin and red cells compared with thrombi that occur secondary to intravascular coagulation.



- patients with TTP have unusually large multimers of von willebrand factor (vWF) in their plasma.
- they have functional deficiency of a plasma protease (designated ADAMTS13) that is responsible for the breakdown of these ultralarge vWF multimers.
- the accumulation of ultralarge vWF multimers on the endothelial surface results in platelet aggregation and eventually thrombus formation

## Thrombotic Thrombocytopenic Purpura



---

➤ TTP can affect any organ system, but involvement of the peripheral blood, the central nervous system, and the kidneys causes the clinical manifestations

➤ In its full-blown form, the disease consists of the following pentad:


- Microangiopathic hemolytic anemia
- Thrombocytopenic purpura
- Neurologic abnormalities
- Fever
- Kidney disease

# Diagnosis and treatment

---

*#Laboratory studies for suspected TTP include:*

- *CBC with platelet count.*
- *peripheral blood smear.*
- *coagulation studies*(Normal PT, PTT, D-Dimer but elevated BT).
- **Signs of hemolysis:** Increase LDH, Increase indirect bilirubin  
Decrease Haptoglobin
- *BUN and creatinine.*
- *Measuring ADAMTS13 activity level.*
- **Treatment:**
  - The therapy of choice for TTP is plasma exchange with fresh frozen plasma



# Hemolytic Uremic Syndrome (HUS)

---

Hemolytic-uremic syndrome (HUS) is a clinical syndrome characterized by progressive kidney failure that is associated with microangiopathic (nonimmune, Coombs-negative) hemolytic anemia and thrombocytopenia.

HUS is the most common cause of acute kidney injury in children .

\* Resemble TTP but:

- More seen in pediatric population
- After viral/bacterial infection
- Pathologic thrombi almost always limited to glomerular capillaries

---

Damage to endothelial cells by E. coli O157:H7 toxin is the primary event in the pathogenesis of hemolytic-uremic syndrome (HUS).

The cardinal lesion is composed of arteriolar and capillary microthrombi (thrombotic microangiopathy [TMA]) and red blood cell (RBC) fragmentation.

Platelet microaggregate (Hyaline microthrombi) formation, usually limited to the glomerular capillaries.

# Lab: Normal PT, PTT, D-Dimer but elevated BT.

# Rx: Conservative



**Microangiopathic hemolytic anemia**  
(Schistocytes)



**Thrombocytopenia**



**Renal insufficiency**

# Thrombocytopenia and COVID-19

---

- Thrombocytopenia is infrequently seen in mild or asymptomatic cases of COVID-19. Of patients with moderate to severe COVID-19, 5-40% develop thrombocytopenia.
- A meta-analysis suggested an association between thrombocytopenia at admission and increased severity of COVID-19.
- Multiple mechanisms are involved in the pathogenesis of COVID-19–related thrombocytopenia, including:
  - bone marrow suppression.
  - platelet consumption in microthrombi in the lung.
  - platelet destruction by autoantibodies and immune complexes.

